MedTrace Logo

FSME IMMUN NEW Follow-up to Study 208 in Volunteers Aged 16 to 66 Years

NCT00161876 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 3973

Last updated 2015-05-21

No results posted yet for this study

Summary

The aim of this study is to evaluate the safety of the third vaccination with FSME-IMMUN NEW in all volunteers who received both vaccinations in Baxter study 208 (safety study of FSME IMMUN NEW and ENCEPUR in healthy volunteers aged 16 to 65 years).

Conditions

  • Encephalitis, Tick-borne

Interventions

BIOLOGICAL

Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)

Sponsors & Collaborators

Principal Investigators

  • Jerzy Romaszko, MD · PANTAMED sp. z o o.

  • Jerzy Brzostek, MD · Zespol Opieki Zdrowotnej w Debicy

  • Jerzy Dziduch, MD · Samodzielny Publiczny Zaklad Opieki Zdrowotnej Oddzial Pediatryczny

  • Krystyna Jurowska, MD · Przedsiebiorstwo Uslug Medycznych "Centrum Medyczne Nowa Huta"

  • Marian Patrzalek, MD · Wojewodzki Szpital Dzieciecy Oddzial Obserwacyjno - Zakazny A

  • Krzysztof Sladek, MD · "Atopia" Diagnostyka i Leczenie Chorob Alergicznych i Ukladu Oddechowego

  • Ryszard Konior · Szpital Jana Pawla II Oddzial Neuoinfekcji

  • Grazyna Zawada-Skrobisz, MD · Oddzial Chorob Zakaznych Specjalistyczny Szpital, Tarnow

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Max Age
66 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2002-05-31
Completion
2002-08-31

Countries

  • Poland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00161876 on ClinicalTrials.gov